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Cultured human glomerular mesangial cells express the C5a
receptor.
Background. While the association of complement activation
and glomerulonephritis has been recognized for decades, the
pathogenic mechanisms of complement-mediated glomerular
damage are incompletely understood. Expression of the C5a
receptor in the kidney suggests that C5a could play a direct role in
initiating or promoting glomerulonephritis.
Methods. Expression of the C5a receptor by cultured human
glomerular mesangial cells (HGMC) was examined by immuno-
fluorescence, by FACS analysis and by reverse transcriptase-
polymerase chain reaction (RT-PCR). Potential mitogenic effects
were examined by analysis of neutral red dye uptake after
treatment with recombinant C5a (rC5a). The production of
cytokines [interleukin-1 (IL-1), interleukin-8 (IL-8), and mono-
cyte chemoattractant protein-1 (MCP-1)] and growth factors
[transforming growth factor-b (TGF-b) and platelet-derived
growth factor (PDGF-AB)] by mesangial cells stimulated with
rC5a was examined by ELISA of cell culture supernatants.
Results. Expression of the C5a receptor by the cultured HGMC
was demonstrated by both immunofluorescence and FACS. The
presence of mRNA encoding the receptor was confirmed by
RT-PCR. Treatment of HGMC in vitro with rC5a resulted in mild
cellular proliferation. No IL-1 was detected despite stimulation
with up to 100 nM rC5a. Concentrations of IL-8 and TGF-b did
not increase beyond basal levels in control samples at any level of
stimulation. Mean MCP-1 concentrations and PDGF-AB concen-
trations increased by 40% and 70% above control values 48 hours
post-stimulation (P 5 0.01 and P 5 0.003, respectively).
Conclusions. These data indicate that the C5a receptor is
expressed on HGMC in vitro, and may play a role in mediating
glomerular injury by promoting cellular proliferation and the
production of cytokines and growth factors.
Activation of the complement cascade, via either the
classical or alternative pathway, results in the production of
C5 convertase that cleaves the fifth component of comple-
ment to generate two fragments, C5a and C5b [1]. C5a, the
smaller cleavage fragment, is composed of the 74 amino
terminal amino acids of the C5 a chain, and has a molec-
ular weight of 11,200 [2]. This small cationic glycopeptide is
a potent immune mediator that, acting through its receptor,
has wide ranging immune-regulatory functions. The C5a
receptor is a member of the rhodopsin family of G-protein
coupled receptors that contain seven transmembrane seg-
ments [3, 4]. Although originally believed to be expressed
primarily on phagocytic cells, the receptor is now known to
be expressed on a wide variety of cell types [4–6]. C5a
mediates histamine release from mast cells, is an extremely
potent chemoattractant for neutrophils, and induces the
production of both cytokines and oxygen free radicals [1, 3,
4, 7–11]. It has been shown to play a central role in the
development of acute lung injury by its ability to induce
chemotaxis and through the up-regulation of cell surface
adhesion molecules [12–14]. It causes smooth muscle con-
traction, and mediates alterations in both vascular tone and
permeability [1]. While investigation has focused on the
role of C5a in complement-mediated pulmonary injury and
in the systemic effects of C5a production by complement
activation on artificial membranes, recent work has shown
that the C5a receptor is expressed both in the liver and in
the kidney and plays a role in regulating the hepatic acute
phase response [14–18]. These and other data suggest that
C5a may play a broader biologic role than was previously
suspected. Little is known regarding the expression of the
C5a receptor in the kidney, and its role, if any, in the
pathogenesis of glomerulonephritis remains obscure.
The association of complement activation and glomeru-
lonephritis has been known for decades. There is strong
clinical evidence supporting a role for complement-medi-
ated injury in a wide range of nephritides. These include
those with evidence for ongoing complement activation,
such as acute post-streptococcal glomerulonephritis, hyper-
acute transplant rejection, and membranoproliferative glo-
merulonephritis, in addition to those in which data suggest
a direct role for complement-mediated injury, as in mem-
branous nephropathy and lupus nephritis [19, 20]. Animal
data, particularly in Heymann’s nephritis, a rat model of
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membranous nephropathy, provides strong evidence for a
causal role for complement in glomerular injury [21]. The
terminal components of the complement cascade, C5b-C9,
play a central role in initiation and perpetuation of im-
mune-mediated damage in both idiopathic membranous
nephropathy and in the Heymann nephritis model [21–23].
However, the relative role of other immuno-active comple-
ment components, such as C3b, C3a, and C5a, remains
obscure. Many of the mediators implicated in glomerular
injury, such as tumor necrosis factor-a (TNF-a), interleu-
kin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and
monocyte chemoattractant protein-1 (MCP-1), as well as
growth factors like transforming growth factor-b (TGF-b),
platelet-derived growth factor (PDGF), and basic fibroblast
growth factor (bFGF), are also known to be regulated in
some cell types by the products of complement activation
(C5a or C5b-9) [8–11, 24]. The role of the various comple-
ment components and their relative effects on the induc-
tion or repression of these mediators is an active and
ongoing area of investigation.
It has been assumed that the primary effects of C5a on
the development of glomerular injury is via its local effects
on chemotaxis, and the attraction of phagocytes to the
injured glomerulus [25]. We hypothesized that C5a also
might have a direct effect on glomerular injury via glomer-
ular expression of its receptor, and that activation of this
receptor may play a role in the development of glomeru-
lonephritis. In support of this hypothesis, we have demon-
strated the expression of the C5a receptor on cultured
human glomerular mesangial cells (HGMC), and charac-
terized the morphologic and proliferative response of these
cells to recombinant C5a (rC5a) stimulation, as well as the
C5a-induced production of Il-1b, IL-8, MCP-1, TGF-b, and
PDGF-AB.
METHODS
Mesangial cell characterization and culture conditions
Primary human glomerular cells from a 16-week-old
fetus were obtained from Clonetics (San Diego, CA, USA).
The cells were characterized by the supplier, using immu-
nofluorescence, as cytokeratin negative, von Willebrand
factor VIII negative, and fibronectin positive. The cells
were cultured at 37°C, 5% CO2 in MsBM
y medium
(Clonetics) with MsGM singlequoty supplements (Clonet-
ics). HGMC were used in these studies between passages 4
and 10. At the time of final passage, the cells were
re-characterized to confirm phenotype stability. Using im-
munofluorescence, the cells were negative for cytokeratin,
von Willebrand factor VIII, CD31, and CD68, and were
positive for fibronectin, vimentin, and a smooth muscle
actin.
Immunofluorescence
Human glomerular mesangial cells (HGMC) were
seeded on glass coverslips. Four days after passage, the
coverslips were washed twice with PBS, fixed for five
minutes in cold 100% acetone, and air dried for five
minutes. The coverslips were then washed twice with PBS,
and incubated for one hour in PBS, 5% non-fat dry milk,
and 3% BSA. IgG from antiserum prepared by immuniza-
tion of rabbits with a peptide consisting of amino acid
residues 7 to 24 of the first extracellular domain of the C5a
receptor (a gift from Dr. R. Wetsel) [17, 18] or from control
rabbit anti-hemoglobin antiserum was purified using a
HiTrapy protein-G column (Pharmacia, Piscataway, NJ,
USA) and reconstituted to equivalent concentration with
PBS. Primary antibodies were diluted 1:15 with PBS, 5%
non-fat dry milk, and 3% BSA, incubated for two hours,
and then washed three times with PBS, 1% Triton X-100,
and 0.2% Tween-20. This was followed by incubation with
fluorescein labeled goat anti-rabbit antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted 1:20 with
PBS, 5% non-fat dry milk, and 3% BSA. The coverslips
were again washed three times with PBS, 1% Triton X-100,
and 0.2% Tween-20, and counterstained with propidium
iodide. Photomicrographs were then obtained using iden-
tical exposure times.
FACS analysis
One week after passage, HGMC were detached from
culture plates with collagenase/EDTA, washed with ice
cold PBS, and stained with a murine monoclonal FITC
conjugated anti-C5a receptor antibody that recognized the
extracellular peptide corresponding to residues 1-31 (clone
W17/1; RDI, Flanders, NJ, USA), or an FITC conjugated
isotype matched control antibody (Caltag Laboratories,
Burlingame, CA, USA). FACS analysis was performed with
a FACScan instrument (Becton-Dickinson).
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total mRNA was obtained from cultured U937 cells,
normal human liver and cultured HGMC using Rneasy
(Qiagen, Santa Clarita, CA, USA) [26]. Reverse transcrip-
tion was performed with Superscript II (Gibco BRL, Gaith-
ersburg, MD, USA) with 2.5 mg mRNA as template, and
standard protocols. The first strand synthesis was followed
by PCR amplification using C5a receptor specific primers.
The forward primer corresponded to nucleotides 17-36
(ATACCACCCCTGATTATGG), and the reverse primer
to nucleotides 206-225 (GAACCAGATGGCATTGATGG)
(GeneBank accession #X58674). The segment amplified
spanned the estimated 9 kb intronic sequence. Amplifica-
tion was performed using DNA polymerase (Gibco BRL)
under the following conditions: denaturation 94°C for three
minutes, 35 cycles of 94°C for one minute, 54°C for 90
seconds, and 70°C for two minutes, and extension at 70°C
for five minutes. The PCR product (20 ml) from the HGMC
digested with Bmo II (New England Biolabs), 10 ml of each
RT-PCR sample, and a 25 bp ladder (Gibco BRL) were
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Fig. 1. Expression of the C5a receptor by cultured human glomerular mesangial cells (HGMC). (A) Cell surface immunofluorescence of HGMC using
rabbit anti-C5a receptor antibody. (B) Negative control using rabbit anti-hemoglobin antibody. Magnification is 340.
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resolved on a 5% acrylamide (2% bis) non-denaturing gel,
and stained with ethidium bromide.
Cellular proliferation
Human glomerular mesangial cells were seeded in equal
density on 96 well plates. Three days after passage, the
medium was changed, and rC5a was added in final concen-
trations of 10 nM, 50 nM, 100 nM, and 200 nM. Recombinant
C5a was purchased from Sigma (St. Louis, MO, USA).
Quadruplicate samples, treated and controls lacking rC5a,
were harvested 24, 48, and 72 hours post-incubation,
washed with PBS, and then incubated for two hours with
neutral red dye. The plates were then washed 4 times with
1 3 PBS, and dye uptake was measured at 540 nm [27].
ELISAs for cytokines and growth factors
The HGMC were cultured in six well plates, and grown
to confluence. On the fourth day post-confluence, the
medium was changed and six hours later, recombinant C5a
was added to the conditioned media. For determination of
dose response, rC5a was added to achieve final concentra-
tions of 10 nM, 25 nM, 50 nM, and 100 nM, in addition to
control samples lacking rC5a. The supernatant for these
assays was removed at 24 hours post-incubation. Assays
were performed in duplicate. Time course analysis was
performed in triplicate, with a final rC5a concentration of
25 nM; control samples were incubated without rC5a.
Supernatants were removed at 6, 12, 24, and 48 hours
post-incubation. All samples were stored at 280°C until the
assays were performed. ELISAs were performed for IL-1,
IL-8, MCP-1, TGF-b, and PDGF-AB (R&D Systems,
Minneapolis, MN, USA). All samples and standards were
run in duplicate according to the manufacturer’s instruc-
tions, and sample values determined by regression analysis
from generated standard curves. The sample values for the
TGF-b assays were determined by subtracting the concen-
tration of TGF-b present in the media alone from the
concentration in the experimental samples.
RESULTS
Immunofluorescent and FACS detection of the C5a
receptor
Immunofluorescent staining of the HGMC with the
rabbit anti-C5a receptor antibody demonstrated a strong
cell surface label for the C5a receptor, with the absence of
fluorescence in the samples stained with control antibody
(Fig. 1). FACS analysis with the monoclonal anti-C5a
receptor antibody confirmed the cell surface expression of
the C5a receptor, with an almost tenfold increase in FITC
staining intensity compared to isotype matched FITC la-
beled control antibody (Fig. 2). The C5a receptor, there-
fore, is expressed on the surface of mesangial cells in vitro.
Expression of C5a receptor mRNA
The RT-PCR of each template mRNA, cultured U937
cells and cultured HGMC, produced only the expected 209
bp PCR product. No larger PCR product was observed,
which excludes the PCR amplification of genomic DNA
contaminants (Fig. 3). The PCR amplification of C5a
receptor mRNA was confirmed by restriction digestion
with MboII, which has a single restriction site at position
Fig. 2. FACS analysis of cultured human
glomerular mesangial cells (HGMC) using an
FITC-labeled murine monoclonal antibody to
the C5a receptor in comparison with FITC-
labeled isotype matched control antibody.
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116 of the amplified sequence; this yielded the expected 116
and 93 bp fragments (data not shown).
Enhanced proliferation
The HGMC showed a mild proliferative response to
rC5a stimulation. At 48 hours post-stimulation, the amount
of proliferation as measured by neutral red dye uptake
increased by 20% in samples treated with 10 nM, 50 nM, 100
nM, and 200 nM rC5a. This effect persisted for the course of
the experiment, and at 72 hours resulted in a mean increase
of 20% in dye uptake compared to control samples (P 5
0.02). The change in proliferation, therefore, is limited to
the first 48 hours. The proliferation was induced by low
concentrations of rC5a, and was not augmented by higher
concentrations of rC5a (Fig. 4).
Cytokine/growth factor release
The response of HGMC to rC5a stimulation, as mea-
sured by the production of cytokines and growth factors,
was not uniform. There was no induction of either TGF-b
or IL-8 above basal levels (data not shown) despite treat-
ment with up to 100 nM rC5a. Likewise, no IL-1b could be
detected in the supernatants of either control samples, or
samples treated with up to 100 nM rC5a (data not shown).
Stimulation of the cultured mesangial cells demonstrated
an increased production of MCP-1. The dose response data
showed peak stimulation with 100 nM rC5a at 24 hours
post-incubation, with smaller responses at lower concentra-
tions. Time course analysis demonstrated a 40% induction
of MCP-1 above control levels at 48 hours when stimulated
with 25 nM rC5a (Fig. 5). This was a statistically significant
increase (P 5 0.01). Higher levels of PDGF-AB were noted
with 10 nM rC5a at 24 hours post-stimulation, but the
differences in dose response were not statistically signifi-
cant. A maximal induction of PDGF-AB 71% (P 5 0.003)
above basal values at 48 hours post-incubation was noted
when stimulated with 25 nM rC5a (Fig. 6).
DISCUSSION
The C5a receptor is expressed on the surface of cultured
HGMC [28]. While the precise origin of the glomerular
mesangial cell is not known, work by Sariola et al supported
the hypothesis that they develop either from migrating
endothelial cells or from cells co-migrating with endothelial
cells [29]. The majority of the data, including phenotypic
characterization, support the suggestion that the mesangial
cell is derived from vascular smooth muscle cells or from
fibroblasts that migrate into the glomerulus along with
vascular endothelial cells [30–32]. It is not surprising that
cells derived from these lineages might express the C5a
receptor. The C5a receptor is expressed in vascular endo-
thelium, hepatocytes, smooth muscle, lung parenchyma,
and on many bone marrow derived cell lines, including
Fig. 3. Reverse transcriptase-polymerase chain reaction (RT-PCR) iden-
tification of C5a receptor mRNA in human glomerular mesangial cells
(HGMC). Samples were subjected to electrophoresis on a 5% polyacryl-
amide gel and stained with ethidium bromide. Lane 1, 25 bp ladder; lane
2, blank; lane 3, blank; lane 4, RT-PCR amplified mRNA from U937 cells;
lane 5, RT-PCR amplified mRNA from human liver; lane 6, RT-PCR
amplified mRNA from HGMC. In both the U937 cells and the HGMC,
only the mRNA specific 209 bp product was observed.
Fig. 4. C5a-mediated enhanced proliferation of human glomerular mes-
angial cells (HGMC). Quadruplicate HGMC samples were either un-
treated or treated with 10 nM, 50 nM, 100 nM and 200 nM rC5a. Neutral red
dye uptake was quantitated at 24, 48 and 72 hours, as described in the
Methods section. Symbols are: (F) control; (E) 10 nM; () 50 nM; () 100
nM; (f) 200 nM.
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neutrophils and monocytes [3–6]. While receptor expres-
sion was confirmed in culture, mesangial expression of the
C5a receptor in vivo has not been demonstrated. Studies of
C5a receptor expression in human kidney tissue by immu-
nohistochemistry fail to demonstrate significant receptor
expression in the glomerulus, although it is expressed in
proximal tubular epithelial cells (R. Wetsel, personal com-
munication; M. Braun, unpublished data). This suggests
that either the level of basal expression in normal kidney in
vivo may be below the level of detection by immunohisto-
chemistry, or that induction of receptor expression may
occur in disease states and as such may directly contribute
to pathogenesis.
C5a induced a mild degree of cellular proliferation in
cultured HGMC. C5a has not been noted previously to
potentiate cellular proliferation. While the effect is small in
magnitude, a 20% increase in optical density at 24 and at 72
hours, it clearly shortens the cell doubling time in vitro. In
our experiments, the cells were stimulated for only a brief
time with C5a. Persistent complement activation over a
period of days or weeks may produce a much more
dramatic cumulative effect in vivo. Mesangial proliferation
is a prominent feature of many nephritides that are be-
lieved to be mediated by complement activation products
[19, 20]. While deposition of the terminal complement
components, C5b-9, clearly plays a major part in this
process, our data suggest that stimulation via the C5a
receptor also may play a role, either directly or indirectly, in
the induction of mesangial proliferation. On the other
hand, in the anti-thymocyte serum model of mesangiopro-
liferative glomerulonephritis, studies in C6-deficient rats
indicate that the disease is dependent upon terminal com-
plement component deposition and that C5a does not play
an important role [33].
Fig. 5. Induction of monocyte chemoattractant protein-1 (MCP-1) in
human glomerular mesangial cell (HGMC) supernatants. (A) rC5a
dose-response at 24 hours post-stimulation. (B) Time course analysis of
MCP-1 expression following stimulation with 25 nM rC5a. Each bar plots
the mean of triplicate samples with the bracket indicating 1 SD. Symbols
are: (p) control; (#) 10 nM; (†) 25 nM; (‡) 50 nM; (§) 100 nM. **P 5 0.01.
Fig. 6. Induction of platelet-derived growth factor-AB (PDGF-AB) in
human glomerular mesangial cell (HGMC) supernatants. (A) rC5a
dose-response at 24 hours post-stimulation. (B) Time course analysis of
PDGF-AB expression following stimulation with 25 nM rC5a. Each bar
plots the mean of triplicate samples with the bracket indicating 1 SD.
Symbols are: (p) control; (#) 10 nM; (†) 25 nM; (‡) 50 nM; (§) 100 nM. **P
5 0.003.
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We have also demonstrated that in vitro, HGMC respond
to C5a stimulation by increasing their synthesis of specific
cytokines and growth factors. Peak levels were noted only
after 48 hours post-stimulation. This, combined with an
absence of an immediate increase in supernatant concen-
trations, suggests that the cellular response is an increase in
synthesis rather than simply release of intracellular stores.
While synthesis of IL-1b, IL-8 and TGF-b was not in-
creased, even by stimulation with up to 100 nM rC5a,
MCP-1 and PGDF-AB levels did increase by small, but
statistically significant, amounts. MCP-1 is a member of the
cys-cys subfamily of chemokines, and has been shown to be
produced by a wide range of cells and tissues [34]. Its
primary effect is as a chemotactic signal for the recruitment
of monocytes. Its expression is increased in both crescentic
glomerulonephritis, and proliferative glomerulonephritis,
where it is thought to contribute to monocytic infiltration in
these lesions [35–37]. The induction of its expression by
C5a may provide an additional mechanism by which both
polymorphonuclear cells and monocytes localize to the
glomerulus in complement mediated glomerulonephritis.
The induction of PDGF-AB by C5a provides additional
support for a role for PDGF in nephritis. PDGF, originally
described as a mitogenic peptide stored in platelets, is now
recognized to be produced in many tissues, including
endothelial cells, HGMC, smooth muscle cells, monocytes,
and epithelial cells [38]. It is thought to play a critical role
in regulating the proliferative response to stimulation by
these cells. The PDGF-B knockout mice demonstrate
striking abnormalities in glomerular architecture, with col-
lapsed glomeruli, and an absence of mesangial substructure
[39]. In the kidney, it has been shown to promote cellular
proliferation, matrix expansion, and chemotaxis [38, 40,
41]. The proliferative effects of C5a stimulation are noted
48 hours post-stimulation, concurrent with the detection of
increased levels of PDGF in the cell supernatants, suggest-
ing that the proliferative effect may, in part, be dependent
on PDGF production. In pathologic studies, PDGF expres-
sion has been associated with both MPGN, and graft
rejection [40–42]. The complement dependent anti-thymo-
cyte serum model of mesangial proliferative glomerulone-
phritis is associated with increased expression of both
PGDF-A and PGDF-B, although the exact mechanism by
which this occurs is not clear [41, 42]. Our data suggest that
this response could be, in part, C5a dependent.
Each of the factors studied had been identified in
previous work as being induced in other cell types by C5a
stimulation, and each has been shown to be synthesized by
mesangial cells in response to other stimuli. The selective
induction of MCP-1 and PDGF-AB, and not IL-1b, IL-8, or
TGF-b, suggests that the cytokine response to C5a stimu-
lation in mesangial cells is cell specific and is targeted to the
production of a more limited range of cytokines and growth
factors than in other cell lines such as endothelial cells or
peripheral blood monocytes.
In conclusion, we have demonstrated that the C5a recep-
tor is expressed by HGMC in vitro. Activation of this
receptor by rC5a induces a wide range of effects in the
mesangial cell, including the increased expression of
MCP-1 and of PDGF in cell supernatants, and an increase
in cell proliferation. These data suggest that stimulation of
the C5a receptor may play a role in the development and
progression of complement-mediated glomerulonephritis,
and could provide an additional causal mechanism by
which complement activation induces glomerular injury.
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APPENDIX
Abbreviations used in this article are: bFGF, basic fibroblast growth
factor; C5a, smaller cleavage fragment of C5 convertase; HGMC, human
glomerular mesangial cells; IL, interleukin; MCP-1, monocyte chemoat-
tractant protein-1; PDGF-AB, platelet-derived growth factor-AB; rC5a,
recombinant C5a; RT-PCR, reverse transcriptase-polymerase chain reac-
tion; TGF-b, transforming growth factor beta; TNF-a, tumor necrosis
factor-alpha.
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